Lantheus Holdings Stock Soars on Medicare Reimbursement Proposal

CMS proposes separate payments for high-cost diagnostic radiopharmaceuticals, boosting investor confidence.

Lantheus shares surged over 34% following the CMS proposal announcement.
The new rule suggests separate reimbursement for radiopharmaceuticals costing over $630 per day.
This change aims to ensure patient access to essential but expensive diagnostic tests.
The proposal is expected to become a final rule in November after a 60-day comment period.
Analysts see this move as a positive step for Lantheus' revenue growth, particularly for products like Pylarify.